Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder

Asia-Pacific Psychiatry

Volumn 6, Issue 1, 2014, Pages 62-70

  Takahashi, Michihiro ^a,b   Goto, Taro ^a   Takita, Yasushi ^a   Chung, Sang Keun ^c   Wang, Yufeng ^d   Gau, Susan Shur Fen ^e  

^a Lilly Research Laboratories Japan   (Japan)

^b Terauchi Takahashi Psychiatric Clinic   (Japan)

^c Chonbuk National University Medical School   (South Korea)

^d PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adult; Atomoxetine; Attention deficit hyperactivity disorder; Chinese; Korean; Taiwanese

Indexed keywords

ADULT; ATOMOXETINE; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CHINESE; KOREAN; TAIWANESE;

ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHINA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPYLAMINES; REPUBLIC OF KOREA; TAIWAN; TREATMENT OUTCOME;

EID: 84894372455     PISSN: 17585864     EISSN: 17585872     Source Type: Journal    
DOI: 10.1111/j.1758-5872.2012.00204.x     Document Type: Article

References (34)

1. Adler L.A., Spencer T., Brown T.E., etal. (2009) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 29, 44-50.
2. Barkley R.A. (1998) Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. Guilford Press, New York.
3. Biederman J., Petty C., Fried R., etal. (2006) Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 163, 1730-1738.
4. Bymaster F.P., Katner J.S., Nelson D.L., etal. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 27, 699-711.
5. Chao C.Y., Gau S.S., Mao W.C., Shyu J.F., Chen Y.C., Yeh C.B. (2008) Relationship of attention-deficit-hyperactivity disorder symptoms, depressive/anxiety symptoms, and life quality in young men. Psychiatry Clin Neurosci. 62, 421-426.
6. Cho S.C., Kim B.N., Kim J.W., etal. (2009) Full syndrome and subthreshold attention-deficit/hyperactivity disorder in a Korean community sample: comorbidity and temperament findings. Eur Child Adolesc Psychiatry. 18, 447-457.
7. Conners C.K., Erhardt D., Sparrow M.A. (1999) Conners' Adult ADHD Rating Scales (CAARS). Multi-Health Systems Inc, North Tonawanda, NY.
8. Dell'Agnello G., Maschietto D., Bravaccio C., etal. (2009) Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol. 19, 822-834.
9. Epstein J., Johnson D.E., Conners C.K. (2001) Conners' Adult ADHD Diagnostic Interview for DSM-IV™ Technical Manual. Multi-Health Systems Inc, New York.
10. Fayyad J., De Graaf R., Kessler R., etal. (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 190, 402-409.
11. Fukuhara S., Suzukamo Y. (2004) Manual of SF-36v2™ Japanese version. NPO Institute for Health Outcomes and Process Evaluation Research, Kyoto.
12. Gau S.S., Huang Y.S., Soong W.T., etal. (2007b) A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 17, 447-460.
13. Gau S.S., Kessler R.C., Tseng W.L., etal. (2007a) Association between sleep problems and symptoms of attention-deficit/hyperactivity disorder in young adults. Sleep. 30, 195-201.
14. Golden C.J. (1975) A group version of the Stroop Color and Word Test. J Pers Assess. 39, 386-388.
15. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare, Bethesda, MD.
16. Hamilton M. (1959) The assessment of anxiety states by rating. Br J Med Psychol. 32, 50-55.
17. Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry. 23, 56-62.
18. Hamilton M. (1969) Diagnosis and rating of anxiety. Br J Psychiatry. 3, 76-79.
19. Holman R.B. (1994) Biological effects of central nervous system stimulants. Addiction. 89, 1435-1441.
20. ICH E14 (2005) International Conference on Harmonization Guidelines E14, The Clinical Evaluation of Qt/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Geneva, Switzerland.
21. Kim J.W., Park C.S., Hwang J.W., etal. (2006) Clinical and genetic characteristics of Korean male alcoholics with and without attention deficit hyperactivity disorder. Alcohol Alcohol. 41, 407-411.
22. Lam L.T., Yang L. (2008) Duration of sleep and ADHD tendency among adolescents in China. J Atten Disord. 11, 437-444.
23. Michelson D., Adler L., Spencer T., etal. (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 53, 112-120.
24. Michelson D., Faries D., Wernicke J., etal. (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 108, E83.
25. NIMH (National Institute of Mental Health) (1985) Clinical Global Impression Scale. Psychopharmacol Bull. 21, 839-843.
26. Park S., Cho M.J., Chang S.M., etal. (2011) Prevalence, correlates, and comorbidities of adult ADHD symptoms in Korea: results of the Korean epidemiologic catchment area study. Psychiatry Res. 186, 378-383.
27. Shimizu T., Ochiai H., Asell F., etal. (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet. 18, 48-70.
28. Stroop J.R. (1935) Studies of interference in serial verbal reactions. J Exp Psychol. 18, 643-662.
29. Svanborg P., Thernlund G., Gustafsson P.A., Hägglöf B., Schacht A., Kadesjö B. (2009) Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 18, 725-735.
30. Takahashi M., Takita Y., Goto T., etal. (2011) An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci. 65, 55-63.
31. Takahashi M., Takita Y., Yamazaki K., etal. (2009) A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 19, 341-350.
32. Wang Y., Zheng Y., Du Y., etal. (2007) Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust NZ J Psychiatry. 41, 222-230.
33. Weiss G., Hechtman L.T. (1993) Hyperactive Children Grown up: ADHD in Children, Adolescents and Adults. Guilford Press, New York.
34. Yen J.Y., Yen C.F., Chen C.S., Tang T.C., Ko C.H. (2009) The association between adult ADHD symptoms and Internet addiction among college students: the gender difference. Cyberpsychol Behav. 12, 187-191.